Business Description
Glenmark Life Sciences Ltd
ISIN : INE03Q201024
Compare
Compare
Traded in other countries / regions
543322.India IPO Date
2021-08-06Description
Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 33.19 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | 381.48 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 16.46 | |||||
| Beneish M-Score | -2.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.4 | |||||
| 3-Year EBITDA Growth Rate | 5 | |||||
| 3-Year EPS without NRI Growth Rate | 10.2 | |||||
| 3-Year FCF Growth Rate | -3.9 | |||||
| 3-Year Book Growth Rate | 45.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 14.62 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.88 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.57 | |||||
| 9-Day RSI | 52.56 | |||||
| 14-Day RSI | 50.87 | |||||
| 6-1 Month Momentum % | 22.21 | |||||
| 12-1 Month Momentum % | 60.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.52 | |||||
| Quick Ratio | 3.03 | |||||
| Cash Ratio | 1.14 | |||||
| Days Inventory | 243.35 | |||||
| Days Sales Outstanding | 135.62 | |||||
| Days Payable | 138.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.07 | |||||
| Dividend Payout Ratio | 0.65 | |||||
| 5-Year Yield-on-Cost % | 2.07 | |||||
| Shareholder Yield % | 2.1 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.93 | |||||
| Operating Margin % | 26.21 | |||||
| Net Margin % | 20.11 | |||||
| FCF Margin % | 13.51 | |||||
| ROE % | 17.49 | |||||
| ROA % | 14.29 | |||||
| ROIC % | 19.55 | |||||
| ROC (Joel Greenblatt) % | 28.71 | |||||
| ROCE % | 22.82 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 31.47 | |||||
| Forward PE Ratio | 25.96 | |||||
| PE Ratio without NRI | 31.47 | |||||
| Price-to-Owner-Earnings | 41.71 | |||||
| PEG Ratio | 3.06 | |||||
| PS Ratio | 6.32 | |||||
| PB Ratio | 5.22 | |||||
| Price-to-Tangible-Book | 5.28 | |||||
| Price-to-Free-Cash-Flow | 46.75 | |||||
| Price-to-Operating-Cash-Flow | 32.18 | |||||
| EV-to-EBIT | 22.47 | |||||
| EV-to-EBITDA | 20.41 | |||||
| EV-to-Revenue | 6.07 | |||||
| EV-to-FCF | 44.72 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.75 | |||||
| Price-to-Graham-Number | 2.72 | |||||
| Price-to-Net-Current-Asset-Value | 8.59 | |||||
| Earnings Yield (Greenblatt) % | 4.44 | |||||
| FCF Yield % | 2.16 | |||||
| Forward Rate of Return (Yacktman) % | 12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Glenmark Life Sciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 21,064.52 | ||
| EPS (TTM) (₹) | 34.46 | ||
| Beta | 0.86 | ||
| Volatility % | 38.25 | ||
| 14-Day RSI | 50.87 | ||
| 14-Day ATR (₹) | 49.773244 | ||
| 20-Day SMA (₹) | 1079.1125 | ||
| 12-1 Month Momentum % | 60.97 | ||
| 52-Week Range (₹) | 626.65 - 1335 | ||
| Shares Outstanding (Mil) | 122.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Glenmark Life Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Glenmark Life Sciences Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Glenmark Life Sciences Ltd Frequently Asked Questions
What is Glenmark Life Sciences Ltd(BOM:543322)'s stock price today?
The current price of BOM:543322 is ₹1086.45. The 52 week high of BOM:543322 is ₹1335.00 and 52 week low is ₹626.65.
When is next earnings date of Glenmark Life Sciences Ltd(BOM:543322)?
The next earnings date of Glenmark Life Sciences Ltd(BOM:543322) is 2025-01-24 Est..
Does Glenmark Life Sciences Ltd(BOM:543322) pay dividends? If so, how much?
The Dividend Yield %  of Glenmark Life Sciences Ltd(BOM:543322) is 2.07% (As of Today), Highest Dividend Payout Ratio of Glenmark Life Sciences Ltd(BOM:543322) was 0.83. The lowest was 0.29. And the median was 0.59. The  Forward Dividend Yield % of Glenmark Life Sciences Ltd(BOM:543322) is 0%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers